Biomedical Journal最新文献

{"title":"Secreted proteins encoded by super enhancer-driven genes could be promising biomarkers for early detection of esophageal squamous cell carcinoma","authors":"","doi":"10.1016/j.bj.2023.100662","DOIUrl":"10.1016/j.bj.2023.100662","url":null,"abstract":"<div><h3>Background</h3><p>Early detection of cancer remains an unmet need in clinical practice, and high diagnostic sensitivity and specificity biomarkers are urgently required. Here, we attempted to identify secreted proteins encoded by super-enhancer (SE)-driven genes as diagnostic biomarkers for esophageal squamous cell carcinoma (ESCC).</p></div><div><h3>Methods</h3><p>We conducted an integrative analysis of multiple data sets including ChIP-seq data, secretome data, CCLE data and GEO data to screen secreted proteins encoded by SE-driven genes. Using ELISA, we further identified up-regulated secreted proteins through a small size of clinical samples and verified in a multi-centre validation stage (345 in test cohort and 231 in validation cohort). Receiver operating characteristic curves were used to calculate diagnostic accuracy. Artificial intelligence (AI) method named gradient boosting machine (GBM) were applied for model construction to enhance diagnostic accuracy.</p></div><div><h3>Results</h3><p>Serum EFNA1 and MMP13 were identified, and showed significantly higher levels in ESCC patients compared to normal controls. An integrated Five-Biomarker Panel (iFBPanel) established by combining EFNA1, MMP13, carcino-embryonic antigen, Cyfra21-1 and squmaous cell carcinoma antigen had AUCs of 0.881 and 0.880 for ESCC in test and validation cohorts, respectively. Importantly, the iFBPanel also exhibited good performance in detecting early-stage ESCC patients (0.872 and 0.864). Furthermore, the iFBPanel was further empowered by AI technology which showed excellent diagnostic performance in early-stage ESCC (0.927 and 0.907).</p></div><div><h3>Conclusions</h3><p>Our study suggested that serum EFNA1 and MMP13 could potentially assist ESCC detection, and provided an easy-to-use detection model that might help the diagnosis of early-stage ESCC.</p></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"47 4","pages":"Article 100662"},"PeriodicalIF":4.1,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2319417023000999/pdfft?md5=4504f2fd3690b113780b1da191002a7e&pid=1-s2.0-S2319417023000999-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41177950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sacral magnetic neuromodulation with intermittent theta burst waveform enhances overactive bladder: In vivo study","authors":"Nurida Khasanah ,&nbsp;Hung-Yen Chin ,&nbsp;Wei-Lun Lo ,&nbsp;Bor-Shing Lin ,&nbsp;Hung-Chou Chen ,&nbsp;Jian-Chiun Liou ,&nbsp;Chun-Wei Wu ,&nbsp;Chih-Wei Peng","doi":"10.1016/j.bj.2024.100775","DOIUrl":"10.1016/j.bj.2024.100775","url":null,"abstract":"<div><h3>Background</h3><div>The current treatment options for overactive bladder (OAB) continue to pose challenges for refractory cases and may involve invasive procedures. To assess the potential benefit of non-invasive repetitive peripheral magnetic stimulation (rPMS) on sacral roots using intermittent theta burst stimulation (iTBS) as a treatment option for OAB. The study involved a total of 33 rats, which were divided into three different experimental phases.</div></div><div><h3>Materials and methods</h3><div>To induce bladder overactivity rats were pretreated with a continuous transvesical infusion of 0.5% acetic acid (AA). During bladder infusion, the intravesical pressure was recorded using cystometrography (CMG) to investigate the effects of AA pretreatment and the therapeutic intervention of acute sacral rPMS using iTBS.</div></div><div><h3>Results</h3><div>Pre-application of rPMS with iTBS at a 100% intensity significantly extended the mean first voiding time (Tv) in normal healthy rats to 132%. Acute rPMS iTBS at a 100% intensity resulted in a significant increase of the inter-contraction interval (ICI) to 121%. An AA model was established with continuous saline infusion after 0.5% AA treatment and resulted in significant reductions of Tv to 42% and ICI to 56% of the corresponding control values. Subsequently, rPMS iTBS at a 100% intensity on the sacral nerve effectively inhibited AA-induced bladder overactivity and significantly increased the ICI to 167%–222%. No significant changes in maximum bladder pressure (Pmax) were found.</div></div><div><h3>Conclusions</h3><div>Sacral nerve rPMS with iTBS demonstrated the ability to suppress AA-induced bladder overactivity. This promising modality could be developed as an alternative approach to enhance bladder continence in OAB syndrome patients.</div></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"48 3","pages":"Article 100775"},"PeriodicalIF":4.1,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141765197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired Immune Deficiency Syndrome correlation with SARS-CoV-2 N genotypes","authors":"","doi":"10.1016/j.bj.2023.100650","DOIUrl":"10.1016/j.bj.2023.100650","url":null,"abstract":"<div><h3>Background</h3><p>Epigenetics and clinical observations referring to Betacoronavirus lead to the conjecture that Sarbecovirus may have the ability to infect lymphocytes using a different way than the spike protein. In addition to inducing the death of lymphocytes, thus drastically reducing their population and causing a serious immune deficiency, allows it to remain hidden for long periods of latency using them as a viral reservoir in what is named Long-Covid Disease. Exploring possibilities, the hypothesis is focused on that N protein may be the key of infecting lymphocytes.</p></div><div><h3>Method</h3><p>The present article exhibits a computational assay for the latest complete sequences reported to GISAID, correlating N genotypes with an enhancement in the affinity of the complex that causes immune deficiency in order to determine a good docking with the N protein and some receptors in lymphocytes.</p></div><div><h3>Results</h3><p>A novel high-interaction coupling of N-RBD and CD147 is presented as the main way of infecting lymphocytes, allowing to define those genotypes involved in their affinity enhancement.</p></div><div><h3>Conclusion</h3><p>The hypothesis is consistent with the mutagenic deriving observed on the in-silico assay, which reveals that genotypes N/120 and N/152 are determinant to reduce the Immune Response of the host infecting lymphocytes, allowing the virus persists indefinitely and causing an Acquire Immune Deficiency Syndrome.</p></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"47 3","pages":"Article 100650"},"PeriodicalIF":4.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2319417023000872/pdfft?md5=1edaaac170d38d8c21d14f03478af8b3&pid=1-s2.0-S2319417023000872-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10030002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gut mycobiome in metabolic diseases: Mechanisms and clinical implication","authors":"","doi":"10.1016/j.bj.2023.100625","DOIUrl":"10.1016/j.bj.2023.100625","url":null,"abstract":"<div><p>Obesity, type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) are three common metabolic diseases with high prevalence worldwide. Emerging evidence suggests that gut dysbiosis may influence the development of metabolic diseases, in which gut fungal microbiome (mycobiome) is actively involved. In this review, we summarize the studies exploring the composition changes of gut mycobiome in metabolic diseases and mechanisms by which fungi affect the development of metabolic diseases. The current mycobiome-based therapies, including probiotic fungi, fungal products, anti-fungal agents and fecal microbiota transplantation (FMT), and their implication in treating metabolic diseases are discussed. We highlight the unique role of gut mycobiome in metabolic diseases, providing perspectives for future research on gut mycobiome in metabolic diseases.</p></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"47 3","pages":"Article 100625"},"PeriodicalIF":4.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2319417023000628/pdfft?md5=afebb46db7828c38f6f0185daf91db90&pid=1-s2.0-S2319417023000628-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10045400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparing transvenous coiling and transarterial embolization with Onyx/NBCA for cavernous sinus dural arteriovenous fistulas: A retrospective study in a single center","authors":"Yi-Ming Wu ,&nbsp;Chuan-Min Lin ,&nbsp;Sachin Giri ,&nbsp;Yao-liang Chen ,&nbsp;Chien-Hung Chang ,&nbsp;Ho-Fai Wong","doi":"10.1016/j.bj.2023.100657","DOIUrl":"10.1016/j.bj.2023.100657","url":null,"abstract":"<div><h3>Background</h3><p>Endovascular management is the gold standard for cavernous sinus dural arteriovenous fistulas (CS-dAVFs) in patients with signs of ophthalmoplegia, visual defects, or intolerable clinical symptoms. Although the efficacy of embolization has been confirmed, complications during post-endovascular management have not been compared in a more extensive CS-dAVFs case series. Therefore, we compared the effectiveness and peri-procedural complications of transvenous coiling with those of transarterial embolization (TAE) using liquid embolic agents.</p></div><div><h3>Methods</h3><p>We reviewed 71 patients with CS-dAVFs in one medical center from 2005/7 to 2016/7. We performed seventy-seven procedures on 71 patients, including six recurrent cases. We compared the efficacy and peri-procedural complications of transvenous coiling and TAE.</p></div><div><h3>Results</h3><p>The complete occlusion rate for transvenous coiling was 79.2%, and that for TAE was 75.0%. Findings revealed (1) similar ophthalmoplegia complication rates (<em>p</em> = 0.744); (2) more frequent and permanent CN5 or CN7 neuropathy with liquid embolic agent use (<em>p</em> = 0.031 and 0.028, respectively); and (3) a higher risk of infarction or ICH (<em>p</em> = 0.002 and 0.028, respectively) in response to aggressive TAE.</p></div><div><h3>Conclusion</h3><p>Transvenous cavernous sinus coiling resulted in a similar occlusion rate and lower complication risk than transarterial Onyx/n-butyl cyanoacrylate (NBCA). We can access via an occluded inferior petrosal sinus (even contralateral), and direct transorbital puncture was a safe alternative. TAE with Onyx/NBCA was helpful in cases of oligo-feeders, but multidisciplinary treatment and multi-session TAE were usually needed for patients with multiple feeders and complex fistulas.</p></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"47 3","pages":"Article 100657"},"PeriodicalIF":5.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S231941702300094X/pdfft?md5=2c2370b7a56affdc671763cd91b96b25&pid=1-s2.0-S231941702300094X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10518907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk factors for peri-intubation cardiac arrest: A systematic review and meta-analysis","authors":"Ting-Hao Yang ,&nbsp;Shih-Chieh Shao ,&nbsp;Yi-Chih Lee ,&nbsp;Chien-Han Hsiao ,&nbsp;Chieh-Ching Yen","doi":"10.1016/j.bj.2023.100656","DOIUrl":"10.1016/j.bj.2023.100656","url":null,"abstract":"<div><h3>Background</h3><p>Peri-intubation cardiac arrest (PICA) is an uncommon yet serious complication of intubation. Although some associated risk factors have been identified, the results have been inconsistent. The aim of this study was to systematically review the relevant research and examine the associated risk factors of PICA through meta-analysis.</p></div><div><h3>Methods</h3><p>Studies examining the risk factors for PICA before 1 Nov. 2022 were identified through searches in MEDLINE (OvidSP) and EMBASE. The reported adjusted or unadjusted odds ratios (ORs) and risk ratios (RRs) were recorded. We calculated pooled ORs and created forest plots using a random-effects model to identify the statistically significant risk factors. We assessed the certainty of evidence for each risk factor.</p></div><div><h3>Results</h3><p>Eight studies were included in the meta-analysis. Pre-intubation hypotension, with a pooled OR of 4.96 (95% confidence interval [C.I.]: 3.75–6.57), pre-intubation hypoxemia, with a pooled OR of 4.43 (95% C.I.: 1.24–15.81), and two or more intubation attempts, with a pooled OR of 1.88 (95% C.I.: 1.09–3.23) were associated with a significantly higher risk of PICA. The pooled incidence of PICA was 2.1% (95% C.I.: 1.5%–3.0%).</p></div><div><h3>Conclusions</h3><p>Pre-intubation hypotension, hypoxemia, and more intubation attempts are significant risk factors for PICA. The findings could help physicians identify patients at risk under the acute setting.</p></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"47 3","pages":"Article 100656"},"PeriodicalIF":5.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2319417023000938/pdfft?md5=cfa3fb8a3cf723e56b2f7c3f6430764e&pid=1-s2.0-S2319417023000938-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10145499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A risk stratification model modified from the U.S. guideline could be applied in an Asian population with or without ASCVD: Validation study","authors":"Yu-Chung Hsiao ,&nbsp;Thung-Lip Lee ,&nbsp;Fang-Ju Lin ,&nbsp;Chin-Feng Hsuan ,&nbsp;Chih-Fan Yeh ,&nbsp;Wei-Tien Chang ,&nbsp;Hsien-Li Kao ,&nbsp;Jiann-Shing Jeng ,&nbsp;Yen-Wen Wu ,&nbsp;I-Chang Hsieh ,&nbsp;Ching-Chang Fang ,&nbsp;Kuo-Yang Wang ,&nbsp;Kuan-Cheng Chang ,&nbsp;Tsung-Hsien Lin ,&nbsp;Wayne Huey-Herng Sheu ,&nbsp;Yi-Heng Li ,&nbsp;Wei-Hsian Yin ,&nbsp;Hung-I Yeh ,&nbsp;Jaw-Wen Chen ,&nbsp;Chau-Chung Wu","doi":"10.1016/j.bj.2023.100653","DOIUrl":"10.1016/j.bj.2023.100653","url":null,"abstract":"<div><h3>Background</h3><p>This study aimed to evaluate the performance of a modified U.S. (MUS) model for risk prediction of cardiovascular (CV) events in Asian patients and compare it to European and Japanese models.</p></div><div><h3>Methods</h3><p>The MUS model, based on the US ACC/AHA 2018 lipid treatment guideline, was employed to stratify patients under primary or secondary prevention. Two multi-center prospective observational registry cohorts, T-SPARCLE and T-PPARCLE, were used to validate the scoring system, and the primary outcome was the time to first occurrence/recurrence of major adverse cardiac events (MACEs). The MUS model's performance was compared to other models from Europe and Japan.</p></div><div><h3>Results</h3><p>A total of 10,733 patients with the mean age of 64.2 (SD: 11.9) and 36.5% female were followed up for a median of 5.4 years. The MUS model was validated, with an AUC score of 0.73 (95% CI 0.68–0.78). The European and Japanese models had AUC scores ranging from 0.6 to 0.7. The MUS model categorized patients into four distinct CV risk groups, with hazard ratios (HRs) as follows: very high- vs. high-risk group (HR = 1.91, 95% CI 1.53–2.39), high- vs. moderate-risk group (HR = 2.08, 95% CI 1.60–2.69), and moderate- vs. low-risk group (HR = 3.14, 95% CI 1.63–6.03). After adjusting for the MUS model, a history of atherosclerotic vascular disease (ASCVD) was not a significant predictor of adverse cardiovascular outcomes within each risk group.</p></div><div><h3>Conclusion</h3><p>The MUS model is an effective tool for risk stratification in Asian patients with and without ASCVD, accurately predicting MACEs and performing comparably or better than other established risk models. Our findings suggest that patient management should focus on background risk factors instead of solely on primary or secondary prevention.</p></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"47 3","pages":"Article 100653"},"PeriodicalIF":5.5,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2319417023000902/pdfft?md5=6e47c31c0ef3fb72396469975665e92e&pid=1-s2.0-S2319417023000902-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10000569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"And those who were seen dancing: Human interactions with fungi and vice versa","authors":"Aila Akosua Kattner","doi":"10.1016/j.bj.2024.100755","DOIUrl":"10.1016/j.bj.2024.100755","url":null,"abstract":"<div><p>This issue of the Biomedical Journal features a special section exploring mycobiota. Three articles examine the role of fungi in common metabolic disorders in, <em>Clostridium difficile</em> infection, and in immunocompromised patients. Additionally, the potential and challenges of the metaverse in healthcare are reviewed, alongside a holistic approach to improve patient outcomes in pancreatic cancer. In this issue also possible mechanism contributing to long COVID are discussed, as well as biomarkers that effectively predict sepsis outcomes, and key targets in osteosarcoma progression. Moreover, factors leading to peri-intubation cardiac arrest are analyzed, healthcare strategies from various regions are employed to predict cardiovascular events in Asian populations, two approaches to cavernous sinus dural arteriovenous fistula are compared, and a combination therapy against soft tissue sarcoma is presented.</p></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"47 3","pages":"Article 100755"},"PeriodicalIF":4.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2319417024000581/pdfft?md5=ecf4adc910ccd70d8ca8af07fd7ce50b&pid=1-s2.0-S2319417024000581-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141431302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using time-course as an essential factor to accurately predict sepsis-associated mortality among patients with suspected sepsis","authors":"","doi":"10.1016/j.bj.2023.100632","DOIUrl":"10.1016/j.bj.2023.100632","url":null,"abstract":"<div><h3>Background</h3><p>Biomarker dynamics in different time-courses might be the primary reason why a static measurement of a single biomarker cannot accurately predict sepsis outcomes. Therefore, we conducted this prospective hospital-based cohort study to simultaneously evaluate the performance of several conventional and novel biomarkers of sepsis in predicting sepsis-associated mortality on different days of illness among patients with suspected sepsis.</p></div><div><h3>Methods</h3><p>We evaluated the performance of 15 novel biomarkers including angiopoietin-2, pentraxin 3, sTREM-1, ICAM-1, VCAM-1, sCD14 and 163, E-selectin, P-selectin, TNF-alpha, interferon-gamma, CD64, IL-6, 8, and 10, along with few conventional markers for predicting sepsis-associated mortality. Patients were grouped into quartiles according to the number of days since symptom onset. Receiver operating characteristic curve (ROC) analysis was used to evaluate the biomarker performance.</p></div><div><h3>Results</h3><p>From 2014 to 2017, 1483 patients were enrolled, of which 78% fulfilled the systemic inflammatory response syndrome criteria, 62% fulfilled the sepsis-3 criteria, 32% had septic shock, and 3.3% developed sepsis-associated mortality. IL-6, pentraxin 3, sCD163, and the blood gas profile demonstrated better performance in the early days of illness, both before and after adjusting for potential confounders (adjusted area under ROC curve [AUROC]:0.81–0.88). Notably, the Sequential Organ Failure Assessment (SOFA) score was relatively consistent throughout the course of illness (adjusted AUROC:0.70–0.91).</p></div><div><h3>Conclusion</h3><p>IL-6, pentraxin 3, sCD163, and the blood gas profile showed excellent predictive accuracy in the early days of illness. The SOFA score was consistently predictive of sepsis-associated mortality throughout the course of illness, with an acceptable performance.</p></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"47 3","pages":"Article 100632"},"PeriodicalIF":4.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2319417023000690/pdfft?md5=8c7ed27e8824475c4fc37be363f94c91&pid=1-s2.0-S2319417023000690-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10214096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The synergy of 177Lu-FAPI-46 with tyrosine kinase inhibitor in a sarcoma patient-derived xenograft mouse model","authors":"Jing-Ren Tseng ,&nbsp;Cheng-Lung Hsu ,&nbsp;Hsin-Hua Hsieh ,&nbsp;Kung-Chu Ho ,&nbsp;Yi-Hsiu Chung ,&nbsp;Chun-Yi Wu","doi":"10.1016/j.bj.2024.100744","DOIUrl":"10.1016/j.bj.2024.100744","url":null,"abstract":"<div><h3>Background</h3><p>Given the heterogeneity and high mortality associated with metastatic soft tissue sarcoma, this study aims to evaluate the therapeutic efficacy of combining ¹⁷⁷Lu-FAPI-46 with Pazopanib against this malignancy.</p></div><div><h3>Methods</h3><p>Patient-derived xenograft (PDX)-bearing mice were randomly divided into three groups: the control group, the ¹⁷⁷Lu-FAPI-46 monotherapy group, and the ¹⁷⁷Lu-FAPI-46 combined with Pazopanib therapy group. Therapeutic efficacy was regularly monitored.</p></div><div><h3>Results</h3><p>The microPET imaging showed a 0.84-fold decrease in the T/M ratio of 68Ga-FAPI-46 on day 7/8 post combination therapy, while the control group exhibited a 1.23-fold increase. Combination therapy significantly inhibited tumor proliferation, as evidenced by reduced Ki-67 and increased caspase 3 expressions. Notably, there was no significant body weight loss observed in any group.</p></div><div><h3>Conclusion</h3><p>This study successfully demonstrated the reduction in FAP expression and suppression of tumor volume in sarcoma PDX following the combination therapy of ¹⁷⁷Lu-FAPI-46 with Pazopanib.</p></div>","PeriodicalId":8934,"journal":{"name":"Biomedical Journal","volume":"47 3","pages":"Article 100744"},"PeriodicalIF":4.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2319417024000477/pdfft?md5=d699bc1c7097a9fd7425c027312f9a35&pid=1-s2.0-S2319417024000477-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140903682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}